OMEZA’s OCM will be featured in an approved abstract treating a complex chronic burn patient at Fall SAWC Oct.15-18 in Las Vegas
Approved Abstract: A Retrospective Observational Evaluation of OCM as Primary Therapy for a Thermal Burn Wound in an Adult Private Practice Wound Setting. The abstract will be presented at the 2026 Fall SAWC Conference, in Las Vegas, NV by Dr. Angelina Ferguson. Dr. Ferguson is the Chief Research Officer for Sygnola Research. Sygnola Research Headquarters are based in New Orleans, LA. OMEZA is also currently enrolling patients in 2 randomized clinical trials where advanced wound care is indicated following standard of care failure: Diabetic Foot Ulcer (NCT07161830) and Venous Leg Ulcer (NCT07754526) Please see OMEZA’s website for all peer reviewed publications studying OCM (OMEZA Complete Matrix).
SARASOTA, Fla., Aug. 31, 2026 /PRNewswire-PRWeb/ — “Transforming Wound Care Through Marine Science”
- Omeza® Holdings, Inc. is a U.S.-based ocean biotechnology company developing and commercializing marine-derived peptides and lipid products, with an FDA-cleared product, OCM™, already on the market and ongoing clinical programs to expand reimbursement and indications. Omeza products are formulated and manufactured in Sarasota, Florida. (USA)
This evaluation in a complex patient further supports OMEZA’s published data showing high efficacy and patient satisfaction when treating refractory wounds. Cynthia Flowers CEO
Media Contact
Bernadette Cupit, OMEZA LLC, 1 9083344554, bcupit@omeza.com, https://omeza.com/
SOURCE OMEZA LLC
Related News
NEWS PROVIDED BYOMEZA LLCAug 17, 2026, 07:58 ET Transforming Wound Care Through Marine Science Omeza® Holdings, Inc. is a U.S.-basedocean biotechnology company developing and commercializing marine-derived peptides andlipid products, with an FDA-cleared product, OCM™, already on the market and ongoingclinical programs to expand reimbursement and indications. Omeza products are formulated andmanufactured in the USA. SARASOTA, […]
SARASOTA, Fla., Aug. 13, 2026 /PRNewswire-PRWeb/ — [OMEZA] today announced it has been ranked No. 230th on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most prestigious ranking of the nation’s most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving […]
Connect with Our Experts
Direct your inquiry to the appropriate Omeza division, clinical, scientific, or corporate, and let's advance the future of wound care together.
Contact Us